The abstract is read at the publisher; the summary is JClub's.
CLDN18.2high advanced gastric tumors are linked to a humoral-enriched microenvironment with higher tumor-infiltrating CD20+ B-cell density and reduced first-line ICI benefit.
- Why it matters: Immune features that track with CLDN18.2 expression status are needed to better predict outcomes on immune checkpoint inhibitors and guide CLDN18.2-directed combinations.
- What they did: In 103 HER2-neg/low advanced gastric cancer patients on first-line ICI, multiplex immunohistochemistry across 7,423,483 cells and 2,315 ROIs profiled tumor-immune features, with validation in 1,521 samples and spatial neighborhood analysis plus digital spatial profiling on 480 ROIs.
- The result: CLDN18.2 status alone did not associate with response or survival, but in CLDN18.2low tumors B-cell enrichment was associated with ICI benefit, whereas in CLDN18.2high tumors tumor-compartment B-cell localization and humoral/extrafollicular programs were linked to diminished ICI benefit.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.